Is there a role for verapamil beyond rate control in paroxysmal atrial fibrillation?

Europace. 2022 Mar 2;24(3):355-356. doi: 10.1093/europace/euab225.

Authors

Alexander P Benz^{1

2}, Stefan H Hohnloser^{3

4}

Affiliations

¹ Department of Cardiology, Cardiology I, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany.
² Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
³ Department of Cardiology, J. W. Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany.
⁴ Center of Thrombosis and Hemostasis, Gutenberg-University Mainz, Mainz, Germany.

PMID: 34499716
DOI: 10.1093/europace/euab225

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / physiopathology
Humans
Tachycardia, Paroxysmal* / physiopathology
Verapamil / therapeutic use

Substances

Anti-Arrhythmia Agents
Verapamil